Form 4: United Therapeutics Director Sells Shares Under 10b5-1 Plan

United Therapeutics Director Jan Malcolm sold 700 shares of common stock for $400.29 per share, reducing her direct beneficial ownership to 520 shares.

Summary

• Director Jan Malcolm of United Therapeutics Corp (UTHR) reported a sale of common stock.
• The transaction involved 700 shares disposed of at a price of $400.29 per share.
• The sale occurred on September 9, 2025.
• Following this transaction, Jan Malcolm directly beneficially owns 520 shares of common stock.
• The transaction was executed under a Rule 10b5-1 pre-arranged trading plan.

Sentiment

Score: 5

Explanation: The transaction is a pre-planned sale under a 10b5-1 plan, which is generally considered a neutral event as it's not indicative of new material information.

Positives

• The transaction was conducted under a Rule 10b5-1 plan, indicating a pre-scheduled sale rather than a reaction to recent non-public information.

Negatives

• A director's sale of shares reduces insider ownership, which can sometimes be perceived as a neutral to slightly negative signal by the market.

Industry Context

This is a company-specific insider transaction report and does not directly relate to broader industry trends or competitors.

Stakeholder Impact

• Shareholders may note the reduction in direct beneficial ownership by a director.

Key Dates

Recommendation

The reported transaction is a pre-planned sale by a director under a Rule 10b5-1 plan. Such transactions are typically for personal liquidity or portfolio diversification and do not usually signal a change in the company's fundamental outlook or warrant a shift in investment recommendation.

Keywords

United Therapeutics, UTHR, Insider Trading, Form 4, Stock Sale, Director, Jan Malcolm, 10b5-1 Plan